All IndicationsInfectious Disease
🦠
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
1
Companies
1
Drug Programs
1
Phase 3
0
Upcoming PDUFAs
Competitors
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| ETNB 89bio, Inc. | Pegozafermin | Phase 3 | — | — | — |
Development Stage Distribution
Phase 3
1
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not Financial Advice
All predictions are probabilistic and based on historical data. Past performance does not guarantee future results. Consult a qualified financial advisor.